{"url_path":"/sec/enta/8-k/2026-07-02/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1177648/0001193125-26-294837-index.html","accession_number":"0001193125-26-294837","cik":"0001177648","ticker":"ENTA","issuer_name":"ENANTA PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1177648/0001193125-26-294837-index.html","primary_entity_key":"0001177648","primary_entity_name":"ENANTA PHARMACEUTICALS INC"},"word_count":111,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\n\nNumber\n\n  \n\nExhibit Description\n\n1.1\n  \n[Open Market Sale AgreementSM dated July 2, 2026, by and between Enanta Pharmaceuticals, Inc. and Jefferies LLC](d123412dex11.htm)\n\n5.1\n  \n[Opinion of Foley Hoag LLP](d123412dex51.htm)\n\n23.1\n  \n[Consent of Foley Hoag LLP (included in Exhibit 5.1)](d123412dex51.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDate: July 2, 2026\n \nENANTA PHARMACEUTICALS, INC.\n\n \n\n \nBy:\n \n\n/s/ Jay R. Luly, Ph.D.\n\n \n\n \n\n \nJay R. Luly, Ph.D.\n\n \n\n \n\n \nPresident and Chief Executive Officer"}